SimonTeoh的个人主页 - 老虎社区

SimonTeoh

SimonTeoh

Play safe

IP属地：未知

24关注

2粉丝

0主题

0勋章

2021-12-16

$Atossa Genetics(ATOS)$Long wait

2021-11-05

$Surgalign Holdings, Inc.(SRGA)$Wake up

2021-08-19

$Atossa Genetics(ATOS)$Trust $ATOS

2021-08-13

$Atossa Genetics(ATOS)$Come on

2021-07-31

$Atossa Genetics(ATOS)$I buy more to average ….. $Atos will be back soon

2021-07-27

$Plug Power(PLUG)$☝🏻

2021-07-26

Atos coming soon 🚀

2021-07-22

$Plug Power(PLUG)$🚀🚀🚀

2021-07-20

🚀🚀🚀

2021-07-14

$Atossa Genetics(ATOS)$Good deal😊

2021-07-13

Sounds good

抱歉，原内容已删除

2021-07-12

Sounds good

Pfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote>

2021-07-12

$Atossa Genetics(ATOS)$🚀🚀🚀

2021-07-12

I’m buying

2021-07-10

Like

抱歉，原内容已删除

2021-07-10

$$$

抱歉，原内容已删除

2021-07-10

Potential stocks

XPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote>

2021-07-10

Ok

抱歉，原内容已删除

2021-07-10

Awaiting

抱歉，原内容已删除

2021-07-10

Great

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3570188731963577","uuid":"3570188731963577","gmtCreate":1607094708773,"gmtModify":1624711526339,"name":"SimonTeoh","pinyin":"simonteoh","introduction":"","introductionEn":"","signature":"Play safe","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":24,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.65%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.21","exceedPercentage":"80.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":690637814,"gmtCreate":1639662686811,"gmtModify":1639662686889,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Long wait&nbsp;","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Long wait&nbsp;","text":"$Atossa Genetics(ATOS)$Long wait","images":[{"img":"https://static.tigerbbs.com/c103182f553853eea9010b87f690fc63","width":"1242","height":"2448"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690637814","isVote":1,"tweetType":1,"viewCount":1546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842004157,"gmtCreate":1636119266705,"gmtModify":1636119437810,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRGA\">$Surgalign Holdings, Inc.(SRGA)$</a>Wake up","listText":"<a href=\"https://laohu8.com/S/SRGA\">$Surgalign Holdings, Inc.(SRGA)$</a>Wake up","text":"$Surgalign Holdings, Inc.(SRGA)$Wake up","images":[{"img":"https://static.tigerbbs.com/6c0ff2546acf92212be27d2ae4a90236","width":"1242","height":"2448"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842004157","isVote":1,"tweetType":1,"viewCount":1588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":838145113,"gmtCreate":1629382680832,"gmtModify":1631884384568,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Trust $ATOS","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Trust $ATOS","text":"$Atossa Genetics(ATOS)$Trust $ATOS","images":[{"img":"https://static.tigerbbs.com/b13bf482959bbea557576ddf3b6232d7","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/838145113","isVote":1,"tweetType":1,"viewCount":1717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":897980926,"gmtCreate":1628868056265,"gmtModify":1631884384595,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Come on","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Come on","text":"$Atossa Genetics(ATOS)$Come on","images":[{"img":"https://static.tigerbbs.com/ac3ec033ff0de282a34271dcf2dc2e84","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897980926","isVote":1,"tweetType":1,"viewCount":1327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":806775939,"gmtCreate":1627696974821,"gmtModify":1631884384711,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>I buy more to average&nbsp;….. $Atos will be back soon&nbsp;","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>I buy more to average&nbsp;….. $Atos will be back soon&nbsp;","text":"$Atossa Genetics(ATOS)$I buy more to average ….. $Atos will be back soon","images":[{"img":"https://static.tigerbbs.com/fda1f1b3e87c2b8abfaa9fc76c1ddc72","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806775939","isVote":1,"tweetType":1,"viewCount":1675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":809328066,"gmtCreate":1627349046155,"gmtModify":1631888480800,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>☝🏻","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>☝🏻","text":"$Plug Power(PLUG)$☝🏻","images":[{"img":"https://static.tigerbbs.com/cf5c1491b5657a3cf3d27081803b817c","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809328066","isVote":1,"tweetType":1,"viewCount":2478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":800578798,"gmtCreate":1627310136814,"gmtModify":1631891492550,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Atos coming soon 🚀","listText":"Atos coming soon 🚀","text":"Atos coming soon 🚀","images":[{"img":"https://static.tigerbbs.com/bae327c1d150ad15024e5ad444b06dc6","width":"1125","height":"2534"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800578798","isVote":1,"tweetType":1,"viewCount":2330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172133630,"gmtCreate":1626942928420,"gmtModify":1631888480814,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>🚀🚀🚀","text":"$Plug Power(PLUG)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/b677286e01542f28218968458be8fde6","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172133630","isVote":1,"tweetType":1,"viewCount":1752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":171727850,"gmtCreate":1626767217370,"gmtModify":1631891492553,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"🚀🚀🚀","listText":"🚀🚀🚀","text":"🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/1f038b38ab74c240bcb3fbea0736bd9f","width":"1125","height":"3313"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171727850","isVote":1,"tweetType":1,"viewCount":2684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144996184,"gmtCreate":1626258951648,"gmtModify":1631884384925,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Good deal😊","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Good deal😊","text":"$Atossa Genetics(ATOS)$Good deal😊","images":[{"img":"https://static.tigerbbs.com/222b0e224045530d20d8e06690c0c744","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144996184","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":142451073,"gmtCreate":1626170637292,"gmtModify":1631891492554,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Sounds good&nbsp;","listText":"Sounds good&nbsp;","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142451073","repostId":"2151964557","repostType":2,"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148755609,"gmtCreate":1626023264101,"gmtModify":1631891492558,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Sounds good&nbsp;","listText":"Sounds good&nbsp;","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148755609","repostId":"2150330031","repostType":2,"repost":{"id":"2150330031","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626022227,"share":"https://www.laohu8.com/m/news/2150330031?lang=zh_CN&edition=full","pubTime":"2021-07-12 00:50","market":"us","language":"en","title":"Pfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2150330031","media":"Reuters","summary":"WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health o","content":"<p><html><body>WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday. </p><p><blockquote><html><body>路透华盛顿7月11日-COVID-19疫苗制造商辉瑞公司周日表示，该公司最早将于周一与联邦卫生官员会面，讨论在准备寻求授权时是否需要加强剂量的冠状病毒疫苗。</body></html></blockquote></p><p>   The meeting comes days after the drugmaker and its partner  <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation. </p><p><blockquote>这次会议是在制药商及其合作伙伴几天后举行的<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>在变种传播的情况下，他们宣布计划寻求美国和欧洲监管机构批准第三剂COVID-19疫苗，他们说数据显示首次接种六个月后感染风险增加。</blockquote></p><p>   That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.</p><p><blockquote>这一推动促使美国迅速做出反应。美国食品药品监督管理局和疾病控制与预防中心表示，美国人现在不需要加强剂。</blockquote></p><p>   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.</p><p><blockquote>公司发言人表示，周一，辉瑞计划与FDA代表会面。《华盛顿邮报》首先报道了这次会议。</blockquote></p><p>   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment. </p><p><blockquote>美国代表。卫生与公众服务部没有立即回应置评请求。</blockquote></p><p>   Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.     </p><p><blockquote>据《华盛顿邮报》报道，乔·拜登总统的首席医疗顾问、国家过敏和传染病研究所所长安东尼·福奇以及美国国立卫生研究院和疾病预防控制中心的负责人也受邀参加简报会，简报会可能会推迟到另一天。</blockquote></p><p>   Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.     </p><p><blockquote>福奇在周日的几次电视采访中表示，美国卫生官员并不排除未来可能需要加强剂——特别是在已接种疫苗的人中出现突破性感染的情况下——但任何正式建议都需要更多数据。</blockquote></p><p>   \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program. </p><p><blockquote>“现在发生了很多动态的事情，”他告诉美国广播公司新闻的“本周”节目。</blockquote></p><p>   \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\" </p><p><blockquote>他在美国有线电视新闻网(CNN)的“状态”节目中补充道：“当我们谈论是否以及何时应该提高员工的可行性时，目前正在进行一些研究……正在进行大量工作来实时检查这一点。”联盟。”</blockquote></p><p>   Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"    </p><p><blockquote>尽管FDA和CDC发表了声明，“这并不意味着我们没有非常非常积极地跟踪和收集所有这些信息，看看我们是否以及何时可能需要它，如果以及何时需要它，我们将拥有一切。”</blockquote></p><p>   U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.  </p><p><blockquote>美国卫生官员仍在努力让一些地区的人们接受首次疫苗接种，因为高传染性德尔塔变异毒株已成为美国的主要毒株，COVID-19病例主要在未接种疫苗的人群中增加。</blockquote></p><p>   European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.</p><p><blockquote>欧洲官员还表示，疫苗目前似乎可以抵御变种。加拿大还表示，正在监测变种以及可能对助推器的需求。</blockquote></p><p>   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.  </p><p><blockquote>虽然一些科学家也质疑加强注射的必要性，但其他人表示，这可能对老年人和其他弱势群体有益，尽管尚不清楚何时需要加强注射。</blockquote></p><p>   Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.</p><p><blockquote>一些公共卫生专家还表示担心，在富裕发达国家授权加强剂，而其他国家仍在努力进行初始接种，将进一步加剧疫苗不平等。</blockquote></p><p> (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)</p><p><blockquote>（Susan Heavey和Chris Prentice报道；Linda So补充报道；Chizu Nomiyama编辑）</blockquote></p><p>((sheavey@thomsonreuters.com; +1-202-898-8300;))</p><p><blockquote>（（sheavey@thomsonreuters.com；+1-202-898-8300；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-07-12 00:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday. </p><p><blockquote><html><body>路透华盛顿7月11日-COVID-19疫苗制造商辉瑞公司周日表示，该公司最早将于周一与联邦卫生官员会面，讨论在准备寻求授权时是否需要加强剂量的冠状病毒疫苗。</body></html></blockquote></p><p>   The meeting comes days after the drugmaker and its partner  <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation. </p><p><blockquote>这次会议是在制药商及其合作伙伴几天后举行的<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>在变种传播的情况下，他们宣布计划寻求美国和欧洲监管机构批准第三剂COVID-19疫苗，他们说数据显示首次接种六个月后感染风险增加。</blockquote></p><p>   That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.</p><p><blockquote>这一推动促使美国迅速做出反应。美国食品药品监督管理局和疾病控制与预防中心表示，美国人现在不需要加强剂。</blockquote></p><p>   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.</p><p><blockquote>公司发言人表示，周一，辉瑞计划与FDA代表会面。《华盛顿邮报》首先报道了这次会议。</blockquote></p><p>   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment. </p><p><blockquote>美国代表。卫生与公众服务部没有立即回应置评请求。</blockquote></p><p>   Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.     </p><p><blockquote>据《华盛顿邮报》报道，乔·拜登总统的首席医疗顾问、国家过敏和传染病研究所所长安东尼·福奇以及美国国立卫生研究院和疾病预防控制中心的负责人也受邀参加简报会，简报会可能会推迟到另一天。</blockquote></p><p>   Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.     </p><p><blockquote>福奇在周日的几次电视采访中表示，美国卫生官员并不排除未来可能需要加强剂——特别是在已接种疫苗的人中出现突破性感染的情况下——但任何正式建议都需要更多数据。</blockquote></p><p>   \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program. </p><p><blockquote>“现在发生了很多动态的事情，”他告诉美国广播公司新闻的“本周”节目。</blockquote></p><p>   \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\" </p><p><blockquote>他在美国有线电视新闻网(CNN)的“状态”节目中补充道：“当我们谈论是否以及何时应该提高员工的可行性时，目前正在进行一些研究……正在进行大量工作来实时检查这一点。”联盟。”</blockquote></p><p>   Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"    </p><p><blockquote>尽管FDA和CDC发表了声明，“这并不意味着我们没有非常非常积极地跟踪和收集所有这些信息，看看我们是否以及何时可能需要它，如果以及何时需要它，我们将拥有一切。”</blockquote></p><p>   U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.  </p><p><blockquote>美国卫生官员仍在努力让一些地区的人们接受首次疫苗接种，因为高传染性德尔塔变异毒株已成为美国的主要毒株，COVID-19病例主要在未接种疫苗的人群中增加。</blockquote></p><p>   European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.</p><p><blockquote>欧洲官员还表示，疫苗目前似乎可以抵御变种。加拿大还表示，正在监测变种以及可能对助推器的需求。</blockquote></p><p>   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.  </p><p><blockquote>虽然一些科学家也质疑加强注射的必要性，但其他人表示，这可能对老年人和其他弱势群体有益，尽管尚不清楚何时需要加强注射。</blockquote></p><p>   Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.</p><p><blockquote>一些公共卫生专家还表示担心，在富裕发达国家授权加强剂，而其他国家仍在努力进行初始接种，将进一步加剧疫苗不平等。</blockquote></p><p> (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)</p><p><blockquote>（Susan Heavey和Chris Prentice报道；Linda So补充报道；Chizu Nomiyama编辑）</blockquote></p><p>((sheavey@thomsonreuters.com; +1-202-898-8300;))</p><p><blockquote>（（sheavey@thomsonreuters.com；+1-202-898-8300；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150330031","content_text":"WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday.    The meeting comes days after the drugmaker and its partner  BioNTech SE    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation.    That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment.    Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.        Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.        \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program.    \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\"    Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"       U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.     European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.     Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity. (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)((sheavey@thomsonreuters.com; +1-202-898-8300;))","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148752766,"gmtCreate":1626022943655,"gmtModify":1631884384963,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>🚀🚀🚀","text":"$Atossa Genetics(ATOS)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/05dc47b34c0ada1e3fefade7399550f5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148752766","isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148752921,"gmtCreate":1626022749663,"gmtModify":1631891492561,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"I’m buying&nbsp;","listText":"I’m buying&nbsp;","text":"I’m buying","images":[{"img":"https://static.tigerbbs.com/2a3918a00d848814cb589d5e7d2c62ad","width":"1125","height":"3068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148752921","isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148975394,"gmtCreate":1625924179218,"gmtModify":1631891492566,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/148975394","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148972644,"gmtCreate":1625924061388,"gmtModify":1631891492568,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"$$$","listText":"$$$","text":"$$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148972644","repostId":"1140589344","repostType":2,"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148976319,"gmtCreate":1625923866031,"gmtModify":1631891492570,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Potential stocks","listText":"Potential stocks","text":"Potential stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148976319","repostId":"1131738801","repostType":2,"repost":{"id":"1131738801","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625645247,"share":"https://www.laohu8.com/m/news/1131738801?lang=zh_CN&edition=full","pubTime":"2021-07-07 16:07","market":"us","language":"en","title":"XPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131738801","media":"Tiger Newspress","summary":"XPeng shares fell 3% in premarket trading.\nShares of Chinese electric vehicle maker Xpeng Inc trade ","content":"<p>XPeng&nbsp;shares&nbsp;fell 3% in premarket&nbsp;trading.</p><p><blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bfcb0a6ca8a7d5337dcf5cc5e4831321\" tg-width=\"1284\" tg-height=\"619\">Shares of Chinese electric vehicle&nbsp;maker Xpeng Inc&nbsp;trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.</p><p><blockquote>中国电动汽车制造商小鹏汽车的股价低至159.30港元，较该公司在香港首次双重主要上市时每股165港元的发行价下跌3.5%。</blockquote></p><p> Xpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said</p><p><blockquote>小鹏汽车周三在香港上市，通过出售8500万股股票筹集了18亿美元，该公司首席执行官表示，将基于为国际市场设计的产品平台开发未来的车型</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-07 16:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>XPeng&nbsp;shares&nbsp;fell 3% in premarket&nbsp;trading.</p><p><blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bfcb0a6ca8a7d5337dcf5cc5e4831321\" tg-width=\"1284\" tg-height=\"619\">Shares of Chinese electric vehicle&nbsp;maker Xpeng Inc&nbsp;trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.</p><p><blockquote>中国电动汽车制造商小鹏汽车的股价低至159.30港元，较该公司在香港首次双重主要上市时每股165港元的发行价下跌3.5%。</blockquote></p><p> Xpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said</p><p><blockquote>小鹏汽车周三在香港上市，通过出售8500万股股票筹集了18亿美元，该公司首席执行官表示，将基于为国际市场设计的产品平台开发未来的车型</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131738801","content_text":"XPeng shares fell 3% in premarket trading.\nShares of Chinese electric vehicle maker Xpeng Inc trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.\nXpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said","news_type":1,"symbols_score_info":{"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148978296,"gmtCreate":1625923806115,"gmtModify":1631891492572,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148978296","repostId":"2149399869","repostType":2,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148971382,"gmtCreate":1625923653046,"gmtModify":1631891492576,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Awaiting&nbsp;","listText":"Awaiting&nbsp;","text":"Awaiting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148971382","repostId":"1181198369","repostType":2,"isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148948323,"gmtCreate":1625922572762,"gmtModify":1633936104159,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148948323","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":148975394,"gmtCreate":1625924179218,"gmtModify":1631891492566,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/148975394","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838145113,"gmtCreate":1629382680832,"gmtModify":1631884384568,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Trust $ATOS","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Trust $ATOS","text":"$Atossa Genetics(ATOS)$Trust $ATOS","images":[{"img":"https://static.tigerbbs.com/b13bf482959bbea557576ddf3b6232d7","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/838145113","isVote":1,"tweetType":1,"viewCount":1717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":690637814,"gmtCreate":1639662686811,"gmtModify":1639662686889,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Long wait&nbsp;","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Long wait&nbsp;","text":"$Atossa Genetics(ATOS)$Long wait","images":[{"img":"https://static.tigerbbs.com/c103182f553853eea9010b87f690fc63","width":"1242","height":"2448"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690637814","isVote":1,"tweetType":1,"viewCount":1546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":809328066,"gmtCreate":1627349046155,"gmtModify":1631888480800,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>☝🏻","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>☝🏻","text":"$Plug Power(PLUG)$☝🏻","images":[{"img":"https://static.tigerbbs.com/cf5c1491b5657a3cf3d27081803b817c","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809328066","isVote":1,"tweetType":1,"viewCount":2478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172133630,"gmtCreate":1626942928420,"gmtModify":1631888480814,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>🚀🚀🚀","text":"$Plug Power(PLUG)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/b677286e01542f28218968458be8fde6","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172133630","isVote":1,"tweetType":1,"viewCount":1752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144996184,"gmtCreate":1626258951648,"gmtModify":1631884384925,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Good deal😊","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Good deal😊","text":"$Atossa Genetics(ATOS)$Good deal😊","images":[{"img":"https://static.tigerbbs.com/222b0e224045530d20d8e06690c0c744","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144996184","isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148948323,"gmtCreate":1625922572762,"gmtModify":1633936104159,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148948323","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":842004157,"gmtCreate":1636119266705,"gmtModify":1636119437810,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRGA\">$Surgalign Holdings, Inc.(SRGA)$</a>Wake up","listText":"<a href=\"https://laohu8.com/S/SRGA\">$Surgalign Holdings, Inc.(SRGA)$</a>Wake up","text":"$Surgalign Holdings, Inc.(SRGA)$Wake up","images":[{"img":"https://static.tigerbbs.com/6c0ff2546acf92212be27d2ae4a90236","width":"1242","height":"2448"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842004157","isVote":1,"tweetType":1,"viewCount":1588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":148752766,"gmtCreate":1626022943655,"gmtModify":1631884384963,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>🚀🚀🚀","text":"$Atossa Genetics(ATOS)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/05dc47b34c0ada1e3fefade7399550f5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148752766","isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148972644,"gmtCreate":1625924061388,"gmtModify":1631891492568,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"$$$","listText":"$$$","text":"$$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148972644","repostId":"1140589344","repostType":2,"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806775939,"gmtCreate":1627696974821,"gmtModify":1631884384711,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>I buy more to average&nbsp;….. $Atos will be back soon&nbsp;","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>I buy more to average&nbsp;….. $Atos will be back soon&nbsp;","text":"$Atossa Genetics(ATOS)$I buy more to average ….. $Atos will be back soon","images":[{"img":"https://static.tigerbbs.com/fda1f1b3e87c2b8abfaa9fc76c1ddc72","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806775939","isVote":1,"tweetType":1,"viewCount":1675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":142451073,"gmtCreate":1626170637292,"gmtModify":1631891492554,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Sounds good&nbsp;","listText":"Sounds good&nbsp;","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142451073","repostId":"2151964557","repostType":2,"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897980926,"gmtCreate":1628868056265,"gmtModify":1631884384595,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Come on","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Come on","text":"$Atossa Genetics(ATOS)$Come on","images":[{"img":"https://static.tigerbbs.com/ac3ec033ff0de282a34271dcf2dc2e84","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897980926","isVote":1,"tweetType":1,"viewCount":1327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":800578798,"gmtCreate":1627310136814,"gmtModify":1631891492550,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Atos coming soon 🚀","listText":"Atos coming soon 🚀","text":"Atos coming soon 🚀","images":[{"img":"https://static.tigerbbs.com/bae327c1d150ad15024e5ad444b06dc6","width":"1125","height":"2534"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800578798","isVote":1,"tweetType":1,"viewCount":2330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":171727850,"gmtCreate":1626767217370,"gmtModify":1631891492553,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"🚀🚀🚀","listText":"🚀🚀🚀","text":"🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/1f038b38ab74c240bcb3fbea0736bd9f","width":"1125","height":"3313"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171727850","isVote":1,"tweetType":1,"viewCount":2684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148755609,"gmtCreate":1626023264101,"gmtModify":1631891492558,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Sounds good&nbsp;","listText":"Sounds good&nbsp;","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148755609","repostId":"2150330031","repostType":2,"repost":{"id":"2150330031","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626022227,"share":"https://www.laohu8.com/m/news/2150330031?lang=zh_CN&edition=full","pubTime":"2021-07-12 00:50","market":"us","language":"en","title":"Pfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2150330031","media":"Reuters","summary":"WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health o","content":"<p><html><body>WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday. </p><p><blockquote><html><body>路透华盛顿7月11日-COVID-19疫苗制造商辉瑞公司周日表示，该公司最早将于周一与联邦卫生官员会面，讨论在准备寻求授权时是否需要加强剂量的冠状病毒疫苗。</body></html></blockquote></p><p>   The meeting comes days after the drugmaker and its partner  <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation. </p><p><blockquote>这次会议是在制药商及其合作伙伴几天后举行的<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>在变种传播的情况下，他们宣布计划寻求美国和欧洲监管机构批准第三剂COVID-19疫苗，他们说数据显示首次接种六个月后感染风险增加。</blockquote></p><p>   That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.</p><p><blockquote>这一推动促使美国迅速做出反应。美国食品药品监督管理局和疾病控制与预防中心表示，美国人现在不需要加强剂。</blockquote></p><p>   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.</p><p><blockquote>公司发言人表示，周一，辉瑞计划与FDA代表会面。《华盛顿邮报》首先报道了这次会议。</blockquote></p><p>   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment. </p><p><blockquote>美国代表。卫生与公众服务部没有立即回应置评请求。</blockquote></p><p>   Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.     </p><p><blockquote>据《华盛顿邮报》报道，乔·拜登总统的首席医疗顾问、国家过敏和传染病研究所所长安东尼·福奇以及美国国立卫生研究院和疾病预防控制中心的负责人也受邀参加简报会，简报会可能会推迟到另一天。</blockquote></p><p>   Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.     </p><p><blockquote>福奇在周日的几次电视采访中表示，美国卫生官员并不排除未来可能需要加强剂——特别是在已接种疫苗的人中出现突破性感染的情况下——但任何正式建议都需要更多数据。</blockquote></p><p>   \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program. </p><p><blockquote>“现在发生了很多动态的事情，”他告诉美国广播公司新闻的“本周”节目。</blockquote></p><p>   \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\" </p><p><blockquote>他在美国有线电视新闻网(CNN)的“状态”节目中补充道：“当我们谈论是否以及何时应该提高员工的可行性时，目前正在进行一些研究……正在进行大量工作来实时检查这一点。”联盟。”</blockquote></p><p>   Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"    </p><p><blockquote>尽管FDA和CDC发表了声明，“这并不意味着我们没有非常非常积极地跟踪和收集所有这些信息，看看我们是否以及何时可能需要它，如果以及何时需要它，我们将拥有一切。”</blockquote></p><p>   U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.  </p><p><blockquote>美国卫生官员仍在努力让一些地区的人们接受首次疫苗接种，因为高传染性德尔塔变异毒株已成为美国的主要毒株，COVID-19病例主要在未接种疫苗的人群中增加。</blockquote></p><p>   European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.</p><p><blockquote>欧洲官员还表示，疫苗目前似乎可以抵御变种。加拿大还表示，正在监测变种以及可能对助推器的需求。</blockquote></p><p>   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.  </p><p><blockquote>虽然一些科学家也质疑加强注射的必要性，但其他人表示，这可能对老年人和其他弱势群体有益，尽管尚不清楚何时需要加强注射。</blockquote></p><p>   Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.</p><p><blockquote>一些公共卫生专家还表示担心，在富裕发达国家授权加强剂，而其他国家仍在努力进行初始接种，将进一步加剧疫苗不平等。</blockquote></p><p> (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)</p><p><blockquote>（Susan Heavey和Chris Prentice报道；Linda So补充报道；Chizu Nomiyama编辑）</blockquote></p><p>((sheavey@thomsonreuters.com; +1-202-898-8300;))</p><p><blockquote>（（sheavey@thomsonreuters.com；+1-202-898-8300；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, U.S. health officials to discuss COVID boosters on Monday -company<blockquote>辉瑞与美国卫生官员将于周一讨论新冠加强剂——公司</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-07-12 00:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday. </p><p><blockquote><html><body>路透华盛顿7月11日-COVID-19疫苗制造商辉瑞公司周日表示，该公司最早将于周一与联邦卫生官员会面，讨论在准备寻求授权时是否需要加强剂量的冠状病毒疫苗。</body></html></blockquote></p><p>   The meeting comes days after the drugmaker and its partner  <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation. </p><p><blockquote>这次会议是在制药商及其合作伙伴几天后举行的<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>在变种传播的情况下，他们宣布计划寻求美国和欧洲监管机构批准第三剂COVID-19疫苗，他们说数据显示首次接种六个月后感染风险增加。</blockquote></p><p>   That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.</p><p><blockquote>这一推动促使美国迅速做出反应。美国食品药品监督管理局和疾病控制与预防中心表示，美国人现在不需要加强剂。</blockquote></p><p>   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.</p><p><blockquote>公司发言人表示，周一，辉瑞计划与FDA代表会面。《华盛顿邮报》首先报道了这次会议。</blockquote></p><p>   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment. </p><p><blockquote>美国代表。卫生与公众服务部没有立即回应置评请求。</blockquote></p><p>   Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.     </p><p><blockquote>据《华盛顿邮报》报道，乔·拜登总统的首席医疗顾问、国家过敏和传染病研究所所长安东尼·福奇以及美国国立卫生研究院和疾病预防控制中心的负责人也受邀参加简报会，简报会可能会推迟到另一天。</blockquote></p><p>   Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.     </p><p><blockquote>福奇在周日的几次电视采访中表示，美国卫生官员并不排除未来可能需要加强剂——特别是在已接种疫苗的人中出现突破性感染的情况下——但任何正式建议都需要更多数据。</blockquote></p><p>   \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program. </p><p><blockquote>“现在发生了很多动态的事情，”他告诉美国广播公司新闻的“本周”节目。</blockquote></p><p>   \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\" </p><p><blockquote>他在美国有线电视新闻网(CNN)的“状态”节目中补充道：“当我们谈论是否以及何时应该提高员工的可行性时，目前正在进行一些研究……正在进行大量工作来实时检查这一点。”联盟。”</blockquote></p><p>   Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"    </p><p><blockquote>尽管FDA和CDC发表了声明，“这并不意味着我们没有非常非常积极地跟踪和收集所有这些信息，看看我们是否以及何时可能需要它，如果以及何时需要它，我们将拥有一切。”</blockquote></p><p>   U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.  </p><p><blockquote>美国卫生官员仍在努力让一些地区的人们接受首次疫苗接种，因为高传染性德尔塔变异毒株已成为美国的主要毒株，COVID-19病例主要在未接种疫苗的人群中增加。</blockquote></p><p>   European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.</p><p><blockquote>欧洲官员还表示，疫苗目前似乎可以抵御变种。加拿大还表示，正在监测变种以及可能对助推器的需求。</blockquote></p><p>   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.  </p><p><blockquote>虽然一些科学家也质疑加强注射的必要性，但其他人表示，这可能对老年人和其他弱势群体有益，尽管尚不清楚何时需要加强注射。</blockquote></p><p>   Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.</p><p><blockquote>一些公共卫生专家还表示担心，在富裕发达国家授权加强剂，而其他国家仍在努力进行初始接种，将进一步加剧疫苗不平等。</blockquote></p><p> (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)</p><p><blockquote>（Susan Heavey和Chris Prentice报道；Linda So补充报道；Chizu Nomiyama编辑）</blockquote></p><p>((sheavey@thomsonreuters.com; +1-202-898-8300;))</p><p><blockquote>（（sheavey@thomsonreuters.com；+1-202-898-8300；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150330031","content_text":"WASHINGTON, July 11 (Reuters) - COVID-19 vaccine maker Pfizer Inc    will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday.    The meeting comes days after the drugmaker and its partner  BioNTech SE    announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation.    That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.   On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.   Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment.    Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.        Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.        \"There's a lot of dynamic things going on right now,\" he told ABC News' \"This Week\" program.    \"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time,\" he added on CNN's \"State of the Union.\"    Despite the FDA and CDC's statement, \"that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it.\"       U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.     European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.   While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.     Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity. (Reporting by Susan Heavey and Chris Prentice; additional reporting by Linda So; Editing by Chizu Nomiyama)((sheavey@thomsonreuters.com; +1-202-898-8300;))","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148752921,"gmtCreate":1626022749663,"gmtModify":1631891492561,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"I’m buying&nbsp;","listText":"I’m buying&nbsp;","text":"I’m buying","images":[{"img":"https://static.tigerbbs.com/2a3918a00d848814cb589d5e7d2c62ad","width":"1125","height":"3068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148752921","isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148976319,"gmtCreate":1625923866031,"gmtModify":1631891492570,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Potential stocks","listText":"Potential stocks","text":"Potential stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148976319","repostId":"1131738801","repostType":2,"repost":{"id":"1131738801","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625645247,"share":"https://www.laohu8.com/m/news/1131738801?lang=zh_CN&edition=full","pubTime":"2021-07-07 16:07","market":"us","language":"en","title":"XPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131738801","media":"Tiger Newspress","summary":"XPeng shares fell 3% in premarket trading.\nShares of Chinese electric vehicle maker Xpeng Inc trade ","content":"<p>XPeng&nbsp;shares&nbsp;fell 3% in premarket&nbsp;trading.</p><p><blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bfcb0a6ca8a7d5337dcf5cc5e4831321\" tg-width=\"1284\" tg-height=\"619\">Shares of Chinese electric vehicle&nbsp;maker Xpeng Inc&nbsp;trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.</p><p><blockquote>中国电动汽车制造商小鹏汽车的股价低至159.30港元，较该公司在香港首次双重主要上市时每股165港元的发行价下跌3.5%。</blockquote></p><p> Xpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said</p><p><blockquote>小鹏汽车周三在香港上市，通过出售8500万股股票筹集了18亿美元，该公司首席执行官表示，将基于为国际市场设计的产品平台开发未来的车型</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares fell 3% in premarket trading.<blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-07 16:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>XPeng&nbsp;shares&nbsp;fell 3% in premarket&nbsp;trading.</p><p><blockquote>小鹏汽车股价在盘前交易中下跌3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bfcb0a6ca8a7d5337dcf5cc5e4831321\" tg-width=\"1284\" tg-height=\"619\">Shares of Chinese electric vehicle&nbsp;maker Xpeng Inc&nbsp;trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.</p><p><blockquote>中国电动汽车制造商小鹏汽车的股价低至159.30港元，较该公司在香港首次双重主要上市时每股165港元的发行价下跌3.5%。</blockquote></p><p> Xpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said</p><p><blockquote>小鹏汽车周三在香港上市，通过出售8500万股股票筹集了18亿美元，该公司首席执行官表示，将基于为国际市场设计的产品平台开发未来的车型</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131738801","content_text":"XPeng shares fell 3% in premarket trading.\nShares of Chinese electric vehicle maker Xpeng Inc trade as low as HK$159.30, down 3.5% from the offer price of HK$165 apiece in the company's dual primary listing debut in Hong Kong.\nXpeng, which on Wednesday raised $1.8 bln by selling 85 mln shares in Hong Kong listing, will develop future models based on product platforms designed for international markets, its chief executive said","news_type":1,"symbols_score_info":{"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148978296,"gmtCreate":1625923806115,"gmtModify":1631891492572,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148978296","repostId":"2149399869","repostType":2,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148971382,"gmtCreate":1625923653046,"gmtModify":1631891492576,"author":{"id":"3570188731963577","authorId":"3570188731963577","name":"SimonTeoh","avatar":"https://static.tigerbbs.com/357c30b86d9ab6c2455afb77b479e9eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570188731963577","authorIdStr":"3570188731963577"},"themes":[],"htmlText":"Awaiting&nbsp;","listText":"Awaiting&nbsp;","text":"Awaiting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148971382","repostId":"1181198369","repostType":2,"isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}